Tilray | TRLY - Ebitda


Tilray reported $8.36M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acasti Pharma USD -2.45M 735K Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Aurora Cannabis CAD 18.48M 3.11M Dec/2025
Avita Medical AUD -9.69M 12.21M Dec/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Cronos Group USD -1.41M 1.86M Mar/2026
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 9.34B 440M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
IQVIA Holdings USD 932M 114M Mar/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Moderna USD -790M 582M Dec/2025
Organigram Holdings CAD 5.26M 884K Dec/2025
Organon & Co USD 415M 32M Mar/2026
Revvity USD 272.91M 24M Mar/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Tilray USD 8.36M 1.82M Sep/2025
Viatris USD 1.05B 46.4M Mar/2026
Xeris Pharmaceuticals USD 25.09M 7.67M Dec/2025
Zealand Pharma A/S -727.47M 285.54M Dec/2025